The role of Platelet-activating factor (PAF) in cerebral vasospasm after subarachnoid hemorrhage

血小板激活因子（PAF）在蛛网膜下腔出血后脑血管痉挛中的作用

• 批准号: 06454412
• 负责人: TAKAKU Akira
• 金额: $ 4.22万
• 依托单位: TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1995
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-06454412/
• 关键词: subarachnoid hemorrhage; cerebral vasospasm; platelet-activating factor; 組織化学; 兎

Levels of platelet-activating factor (PAF) in CSF showed gradual increase after the onset of SAH,with a subsequent decrease. The PAF concentration between 5 and 9 days after SAH was greater in patients with cerebral infarction due to vasospasm than in patients without infarction. Conversely, PAFacetylhydrolase activity decreased gradually after SAH,then increased. The enzyme activity for the same period was smaller in patients with cerebral infarction than in patients without infarction. Two peaks of inhibitory activity against PAFacetylhydrolase, void volume and 13kD,were detected on SephacrylS-200HR gel filtration (J Neurosurg 80 : 31-36,1994).Neurological deterioration was largely prevented in the rabbits which received a PAF antagonist, E5880. Basilar artery constriction also was reduced by E5880. Furthermore, E5880 group demonstrated ischemic changes less frequently than the controls. Plasma thromboxane B_2 concentrations were reduced in rabbits treated with E5880. The intravenous administration of E5880 is a promising approach preventing the occurrence of vasospasm (J Neurosurg in press).

脑脊液中血小板活化因子（PAF）水平在SAH发病后逐渐升高，随后下降。由于血管痉挛而发生脑梗死的患者在SAH后5 - 9天的PAF浓度高于无梗死的患者。相反，PAFacetylhydrolase活性在SAH后逐渐降低，然后升高。同一时期脑梗死患者的酶活性低于无梗死患者。用SephacrylS-200HR凝胶过滤法检测了PAFacetylhydrolase的两个抑制峰，空穴体积和13kD (journal of neurojournal)（中国神经外科杂志，80:31-36,1994）。在接受PAF拮抗剂E5880的家兔中，神经退化在很大程度上得到了预防。E5880也能减少基底动脉的收缩。此外，与对照组相比，E5880组出现缺血性改变的频率更低。E5880可降低家兔血浆血栓素B_2浓度。静脉注射E5880是预防血管痉挛发生的一种很有前途的方法（J neurosurgery in press）。

项目成果

Hirashima Y,Endo S,Ohmori T,Kato R,Takaku A: "Platelet-activating factor (PAF) concentration and PAFacetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage." J Neurosurg. 80. 31-36 (1994)

Hirashima Y、Endo S、Ohmori T、Kato R、Takaku A：“蛛网膜下腔出血患者脑脊液中的血小板激活因子 (PAF) 浓度和 PAF 乙酰水解酶活性。”

平島 豊 高久 晃: "CVD GRAND ROUND SERIES Vol.1 Vasospasm ground round" にゅ-ろん社, 192 (1994)

Yutaka Hirashima 和 Akira Takahisa：“CVD GRAND ROUND SERIES Vol.1 Vasospasm ground round”Nyuronsha，192 (1994)

平島豊,野村耕章,大森友明,加藤僚子,遠藤俊郎,高久晃: "くも膜下出血モデルにおけるDAF拮抗薬E5880の脳血管攣縮予防効果" 脳血管攣縮. 10. 219-223 (1995)

Yutaka Hirashima、Koaki Nomura、Tomoaki Omori、Ryoko Kato、Toshiro Endo、Akira Takaku：“DAF 拮抗剂 E5880 对蛛网膜下腔出血模型中脑血管痉挛的预防作用” Cerebral Vasospasm 10. 219-223 (1995)。

Hirashima Y,Endo S,Kato R,Takaku A: "The Platelet-activating factor antagonist, E5880, prevents cerebrovasospasm following subarachnoid hemorrhage in rabbits." J Neurosurg. (in press).

Hirashima Y、Endo S、Kato R、Takaku A：“血小板激活因子拮抗剂 E5880 可预防兔子蛛网膜下腔出血后的脑血管痉挛。”

Yutaka Hirashima: "Platelet-activating factor and antiphospholipid antibody in subarachnoid haemovrhage" Acta Neurochir(Wien). 128. 144-149 (1994)

Yutaka Hirashima：“蛛网膜下腔出血中的血小板激活因子和抗磷脂抗体”Acta Neurochir（维也纳）。